Novartis solid tumor 'CAR T cell' still holds promise - researcher

April 20 (Reuters) - A new type of immuno-oncology treatment from Novartis AG proved safe in a tiny study of three types of solid tumors, but the trial included too few patients and used too small a dose of the experimental product to prove effectiveness, according to data presented at a cancer meeting on Sunday.